trending Market Intelligence /marketintelligence/en/news-insights/trending/x52xal146lybdysulvehhg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Sucampo upsizes note offering to $260M

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


Sucampo upsizes note offering to $260M

Sucampo Pharmaceuticals Inc. priced and upsized a previously announced debt offering to repay an existing senior secured credit facility.

The company will issue $260 million worth of 3.25% senior notes due 2021, complete with an option to purchase an additional $40 million worth of the debt.

Interest will be payable semiannually starting June 15, 2017. The notes will also convert into class A Sucampo shares at an initial conversion rate of $16.59 per share.

Sucampo initially planned on issuing $225 million of the debt.

Sucampo Pharmaceuticals secured a $250 million credit facility in October 2015 to fund its planned purchase of R-Tech Ueno. The new debt issue could help free up some of the company's cash, given that Sucampo is required to maintain at least $25 million in a restricted cash account until at least $35 million of the facility is repaid or prepaid.

Leerink Partners LLC is the sole book-running manager of the issue. The sale is expected to close Dec. 27.